{"title":"白介素-6受体抑制剂治疗类风湿关节炎的安全性和剂量","authors":"Melania Martínez-Morillo, Dolors Grados, Beatriz Tejera, Alejandro Olivé Marqués","doi":"10.1016/j.semreu.2011.02.003","DOIUrl":null,"url":null,"abstract":"<div><p>Biological therapies may herald the cure for rheumatoid arthritis. Targeted biologic therapies have changed the outcome of this disease. Tocilizumab is a humanized monoclonal antibody against the interleukin-6 receptor and has been approved in many countries for the treatment of moderate to severe rheumatoid arthritis. A number of clinical trials have demonstrated the efficacy of tocilizumab in active rheumatoid arthritis. This review summarizes the data on the safety and dosage of this drug.</p></div>","PeriodicalId":101152,"journal":{"name":"Seminarios de la Fundación Espa?ola de Reumatología","volume":"12 2","pages":"Pages 57-60"},"PeriodicalIF":0.0000,"publicationDate":"2011-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.semreu.2011.02.003","citationCount":"0","resultStr":"{\"title\":\"Inhibidor del receptor de la interleucina-6 en el tratamiento de la artritis reumatoide: seguridad y dosificación del tocilizumab\",\"authors\":\"Melania Martínez-Morillo, Dolors Grados, Beatriz Tejera, Alejandro Olivé Marqués\",\"doi\":\"10.1016/j.semreu.2011.02.003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Biological therapies may herald the cure for rheumatoid arthritis. Targeted biologic therapies have changed the outcome of this disease. Tocilizumab is a humanized monoclonal antibody against the interleukin-6 receptor and has been approved in many countries for the treatment of moderate to severe rheumatoid arthritis. A number of clinical trials have demonstrated the efficacy of tocilizumab in active rheumatoid arthritis. This review summarizes the data on the safety and dosage of this drug.</p></div>\",\"PeriodicalId\":101152,\"journal\":{\"name\":\"Seminarios de la Fundación Espa?ola de Reumatología\",\"volume\":\"12 2\",\"pages\":\"Pages 57-60\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2011-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.semreu.2011.02.003\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Seminarios de la Fundación Espa?ola de Reumatología\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1577356611000273\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminarios de la Fundación Espa?ola de Reumatología","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1577356611000273","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Inhibidor del receptor de la interleucina-6 en el tratamiento de la artritis reumatoide: seguridad y dosificación del tocilizumab
Biological therapies may herald the cure for rheumatoid arthritis. Targeted biologic therapies have changed the outcome of this disease. Tocilizumab is a humanized monoclonal antibody against the interleukin-6 receptor and has been approved in many countries for the treatment of moderate to severe rheumatoid arthritis. A number of clinical trials have demonstrated the efficacy of tocilizumab in active rheumatoid arthritis. This review summarizes the data on the safety and dosage of this drug.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
